Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
received:
10
07
2020
accepted:
26
10
2020
pubmed:
30
10
2020
medline:
29
12
2020
entrez:
29
10
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
Identifiants
pubmed: 33115920
pii: science.abd7728
doi: 10.1126/science.abd7728
pmc: PMC7810037
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227-1230Subventions
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260560
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Influenza Other Respir Viruses. 2020 Mar;14(2):237-243
pubmed: 31837101
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
J Med Virol. 2001 Jan;63(1):1-7
pubmed: 11130881
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781